Dr Maurice Chagnaud to head Lupin's European operation

Dr Maurice Chagnaud has been appointed as Lupin’s President, Europe and Head of Inhalation Strategy. Based at Schaffhausen (Switzerland), Dr Chagnaud will assume full responsibility for Lupin’s European business including the company strategy for generics & specialty business in Western and CEE region including Russia & CIS countries. He will also be responsible for developing Lupin’s core strategy for inhalation in the developed markets.
 
Dr Chagnaud has over 20 years of experience in pharmaceutical business in Europe having worked with Teva and Merck Generics. He joins Lupin from Israeli drug major, Teva, where he was the Senior Vice President, Central & Eastern Europe, responsible for revenues in excess of over Euro 1 billion.
 
Vinita Gupta, Chief Executive Officer, Lupin Limited, said, “Over the years, Lupin has recorded consistent growth across advanced markets like the US and Japan. With Maurice’s rich experience we look forward to building our business in Europe, in particular around complex generics & specialty. We are delighted to welcome him into the Lupin family.”